Exited position

David Abrams’s Akebia Threapeutics Inc (AKBA) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Abrams Capital Management, L.P.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2018Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares5.66MHighest verified quarter-end share count
Quarters reported9Verified quarters with shares above zero
What happened?

Abrams Capital Management, L.P. first reported Akebia Threapeutics Inc in Q3 2018. The reported position was increased across later filings. The latest verified relationship event shows that Abrams Capital Management, L.P. sold the entire position in Q4 2020, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2020
Sold the entire position−5.66M shares · No shares reported at quarter-end
Q4 2018
Bought 405.4% more+4.54M shares · 5.66M shares reported after the change
Filing context

Quarter-end price $5.53 · Estimated holding basis $6.18

Q3 2018
New position+1.12M shares · 1.12M shares reported
Filing context

Quarter-end price $8.83 · Estimated holding basis $8.83

7 unchanged quarters are collapsed by default.

Portfolio importance

How important was Akebia Threapeutics Inc in Abrams Capital Management, L.P.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.4%Q3 2020
Last reported rank#18of 19 reported positions
Peak portfolio weight2.5%Q2 2020
Best historical rank#15Q4 2018
At peak importanceQ2 2020
AKBA
2.5%
Largest holding
10.9%
Cross-investor discovery

Who else owns Akebia Threapeutics Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
AKBA0.0% of reported portfolio
Explore Akebia Threapeutics Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

This tracker follows Abrams Capital Management, L.P.’s Form 13F disclosures, not David Abrams’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.